RTI Biologics, Inc. (RTIX) Tops Q3 EPS by 2c, Raises FY11 Guidance
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Join SI Premium – FREE
RTI Biologics, Inc. (NASDAQ: RTIX) reported Q3 EPS of $0.05, $0.02 better than the analyst estimate of $0.03. Revenue for the quarter came in at $42.3 million versus the consensus estimate of $40.44 million.
RTI Biologics, Inc. sees FY2011 EPS of $0.12-$0.14, versus the consensus of $0.13. RTI Biologics, Inc. sees FY2011 revenue of $164-$166 million, versus the consensus of $165.94 million.
RTI Biologics, Inc. sees FY2011 EPS of $0.12-$0.14, versus the consensus of $0.13. RTI Biologics, Inc. sees FY2011 revenue of $164-$166 million, versus the consensus of $165.94 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
